Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration

Overview of attention for article published in Journal for Immunotherapy of Cancer, May 2019

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (80th percentile)
Above-average Attention Score compared to outputs of the same age and source (61st percentile)

Mentioned by

twitter: 15 X users

facebook: 1 Facebook page

Citations

dimensions_citation: 52 Dimensions

Readers on

mendeley: 62 Mendeley

Summary X Facebook Dimensions citations

So far, Altmetric has seen 29 X posts from 15 X users, with an upper bound of 39,957 followers.

Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration. https://t.co/X6n9WXHPxk

27 Jul 2020

Reply Repost Favourite

RT @sitcancer: #JITC Research: Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patient…

23 Nov 2019

Reply Repost Favourite

RT @AndrewZloza: Very pleased to see that our study of ONC201, the first imipridone to enter clinical development, has already been accesse…

08 Jul 2019

Reply Repost Favourite

RT @AndrewZloza: Very pleased to see that our study of ONC201, the first imipridone to enter clinical development, has already been accesse…

02 Jul 2019

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 25 additional X posts.